TAMPA, FL – October 24, 2023 — WebWire – Essex Partners, LLC, an independent sponsor and affiliate of Essex Capital Group, Inc., announced that it recently closed an add-on acquisition of a skincare product line that includes established, best-in-class scar (ScarMD) and bruise (Hematix) treatments. The acquisition will further diversify the product offering for Essex’s existing platform company, SkinGenuity, LLC.

SkinGenuity has developed leading-edge skincare products that use a combination of bio-engineered growth factors and DNA enzymes to repair and rejuvenate multiple skin issues. Its products are currently sold through a global distribution network.

Paul Guilbaud, SkinGenuity CEO commented, “Adding these scar and bruise treatments to our product mix complements our existing offering while expanding our distribution network into China and South Korea, where these new products are already commercialized. We believe this acquisition gives us a compelling opportunity to grow the scar and bruise revenues through our current global network as well as accelerate SkinGenuity’s sales of existing products in China and South Korea.”

This acquisition marks the third independent sponsor transaction closed by Essex Partners in 2023. Terms of the transaction were not disclosed.

About Essex Partners
Essex Partners, LLC (“EP”) is a private investment platform, seeking to acquire and grow businesses in the lower middle market. Essex Partners’ mandate is to invest in companies with market-leading product positions and sustainable competitive advantages. The strategy includes adding synergistic acquisitions to existing platform investments and assisting in executing organic and inorganic growth initiatives that fuel revenue expansion, optimize operations, and increase enterprise value. To learn more about Essex Capital Group, visit essexcg.com.

About SkinGenuity, ScarMD, Hematix
SkinGenuity distributes a wide range of topical treatments that use breakthrough technology in products for skincare, vaginal atrophy, and hair growth. Learn more at skingenuity.co.uk.

To learn about the product lines associated with this acquisition, please see the product websites: ScarMD (scarmd.net), Hematix, (hematix.com).

About Essex Partners

Essex Partners is an independent sponsor and affiliate of Essex Capital Group, Inc, seeking to acquire and grow businesses in the lower middle market. Essex Partners’ mandate is to invest in companies with market-leading product positions and sustainable competitive advantages. The strategy includes adding synergistic acquisitions to existing platform investments and assisting in executing organic and inorganic growth initiatives that fuel revenue expansion, optimize operations, and increase enterprise value.

To learn more about Essex Capital Group, visit essexcg.com.

Contact

Rob Swain
[email protected]
813.391.2773

Media Inquiries

Tripper Allen
[email protected]
678.575.0711